Study details
Enrolling now
A Phase 1 Trial of WVE-007
Wave Life Sciences Ltd.
NCT IDNCT06842186ClinicalTrials.gov data as of Apr 2026
Phase
Phase 1
Target enrollment
136
Study length
about 1.7 years
Ages
18–60
Locations
1 site in MD
About this study
Researchers are testing the safety and how your body processes WVE-007 when given as a medication under the skin. The trial will last for about two years.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take WVE-007
PhasePhase 1
Primary goalThe proportion of participants with adverse events
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low8%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Endpoints
Primary: The proportion of participants with adverse events
Secondary: Maximum concentration of WVE-007 in plasma (Cmax)